Attovia Therapeutics, Inc. (ATTO) |
| 14.3565 -0.234 (-1.6%) 10-13 09:55 |
| Open: | 14.5 |
| High: | 14.69 |
| Low: | 14.2303 |
| Volume: | 36,694 |
| Market Cap: | 618(M) |
| PE Ratio: | -5.24 |
| Exchange: | NASDAQ |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 28.00 |
| Resistance 1: | 22.82 |
| Pivot price: | 17.48 |
| Support 1: | 14.45 |
| Support 2: | 12.02 |
| 52w High: | 28 |
| 52w Low: | 14.3565 |
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Financials
| EPS | -75250000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -4.00 |
| Return on Assets (ttm) | 845.1 |
| Return on Equity (ttm) | 0.0 |
Company news
Thu, 08 Oct 2026
Form 4 Attovia Therapeutics For: 8 October By Investing.com - Investing.com Nigeria
Thu, 08 Oct 2026
Attovia Therapeutics (ATTO) amends CFO option-grant report with no ownership changes. - Stock Titan
Thu, 08 Oct 2026
No ownership changes: Attovia Therapeutics (ATTO) CEO Tao Fu reports 87,843 direct shares. - Stock Titan
Mon, 28 Sep 2026
Attovia Therapeutics to Present New Data on ATTO-1310 and - GlobeNewswire
Mon, 21 Sep 2026
Attovia Therapeutics (ATTO) Pulls Back As Investors Ask If The Valuation Still Fits - Yahoo Finance
Wed, 05 Aug 2026
Attovia’s Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders - MedCity News
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
